Composition of extract of emblica officinalis and method of preparing the same

ABSTRACT

The present disclosure relates to a composition of an extract of fruits of  Emblica officinalis  selected from the group consisting of liquid juice of fruits of  Emblica officinalis , a powder of an alcoholic extract of fruits of  Emblica officinalis , a powder of a hydro alcoholic extract of fruits of  Emblica officinalis , a powder of a water extract of fruits of  Emblica officinalis , a powder of a juice of fruits of  Emblica officinalis , a powder of dried fruits of  Emblica officinalis , a powder of a water extract of dried fruits of  Emblica officinalis , a powder of a pectinase treated water extract of fruits of  Emblica officinalis , and combinations thereof; a method of preparing such compositions of extract of fruits of  Emblica officinalis , more particularly which has application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer&#39;s disease and for the treatment of memory loss especially in Alzheimer&#39;s disease.

FIELD OF THE INVENTION

The present disclosure relates to a composition of the extract of fruits of Emblica officinalis, a method of preparing a composition consisting of extract of fruits of Emblica officinalis more particularly which has application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

DESCRIPTION OF RELATED ART

In our everyday life almost all the activities in one way or other deal with memory. Loss of memory means loss of one's self. Learning will make no sense if it is not retained by the individual. It is only through memory that we are able to relate different events, experiences, conditions, people, objects etc. Memory is needed in making social relationships, mastering cognitive competencies (mental capacities) and solving various problems.

Memory is a remarkable process and system which receives information from both external and internal stimuli, retains it and makes it available on future occasion. The retrieval of information can be in the same way or in a different form and the reception depends on the information we already have. We neither receive nor retain all the information presented to us because there is a great deal of selectivity in receiving the information. Human memory can retain extremely large amount of information. It is an active system which can integrate, add, modify, omit or reorganize the information.

Since first addressed by Kral (1) in the late 1950s, numerous studies (2, 3, 4, 5, 6, 7, 8) have documented poorer memory performance in older compared with younger age groups. Although the exact prevalence is uncertain, most agree that memory decline occurs in more than 40% of individuals older than 60 years. (9) Despite this high prevalence, or perhaps because of it, there is continued debate about whether memory decline in otherwise healthy older people should be considered a clinical entity. Studies, (10) with humans and animals have shown that memory decline is not inevitable with increasing age and therefore should be considered a clinical entity.

The number and proportion of aging individuals in the population is increasing. These aging individuals expect to lead intellectually challenging lives in an environment rich with information and reliant on rapidly changing technologies. The ability to negotiate this environment depends on cognitive skills that include the specific types of memory systems most vulnerable to age-associated changes. Memory decline interferes with an aging individual's activities of daily living, without necessarily progressing to amnesia or extending into dementia (11, 12, 13).

Because Alzheimer's disease (AD) is relatively common in individuals older than 65 years and because AD pathological processes target the hippocampal formation early in its course, (14) early AD is a major contributor to memory decline in otherwise healthy and nondemented older people. Still, not every older individual with memory deficits progresses to AD dementia. (15, 16)

Currently, there are an estimated 24 million people worldwide with dementia. Two thirds of them live in developing countries. This figure is set to increase to more than 80 million by 2040. Much of this increase will be in rapidly developing and heavily populated regions such as China, India, and Latin America. Alzheimer's disease is by far the commonest cause of dementia in the elderly, being responsible for 65-80 percent of dementia cases (17, 18).

Alzheimer's disease (AD) is a neurodegenerative disorder that results in progressive loss of memory, changes in personality, and cognitive decline. The UN population projections estimate that the number of people older than 80 years will approach 370 million by the year 2050. Currently, it is estimated that 50% of the people over the age of 85 years are afflicted with AD. Therefore, by 2050, more than 100 million people worldwide are likely to suffer from this devastating disease.

One in eight men and almost one in four women will develop Alzheimer's disease during their lifetime. In a population-based study of people older than age 65 years, dementia was the strongest risk factor for mortality, surpassing heart disease, stroke, diabetes, and cancer (19).

The vast number of people requiring constant care and other services can severely strain medical, monetary and human resources. An effective, disease-modifying treatment of Alzheimer's disease remains an unmet need of modern medicine. The dementia of AD has an insidious onset and a gradually progressive course. Although the pathogenesis of the disease remains unclear, the process is widely thought to begin in midlife or earlier, decades before the appearance of symptoms.

The extent and complexity of Alzheimer's disease that affects numerous cells, molecules, systems and pathways, impede attempts to determine which changes are specifically associated with early pathology. Consequently, a number of hypotheses exist, and a number of treatment options are also suggested. The patient, in the meantime, remains at the mercy of the proponents of these hypotheses. Most of the clinical trials have returned negative results. Nearly 50,000 research reports have been published on AD, yet we aren't anywhere near a disease-modifying treatment option which simultaneously addresses the various facets of the disease. Current approaches and proposals address one single aspect and the disappointing results largely arise because of this basic flaw.

A disease-modifying treatment regimen for Alzheimer's disease is an urgent need. Before this can be achieved, we need to understand the mechanism of the disease itself. Various treatment options presently suggested and followed are without clear understanding of the disease process itself, and quite expectedly, all have failed at the clinic.

Despite a previous sharp distinction between vascular and neurodegenerative diseases, evidence linking vascular risk factors and indicators of vascular disease to Alzheimer's disease has accumulated over the past decade. In particular, evidence is growing for a possible association between lipids and Alzheimer's disease or dementia.

The central nervous system is a lipid-rich organ, and approximately 25 percent of the total amount of cholesterol present in humans is localized in the brain and the central nervous system, mainly in the myelin sheath (i.e., oligodendroglia) and the membranes of astrocytes and neurons (20, 21). Lipoprotein complexes are critical for synaptic maturation and maintenance of synaptic plasticity (22, 23) and synaptic growth, regeneration, and neurotic outgrowth depend greatly on the availability of brain lipids (22, 23, 24).

Evidence is growing that lipid-rich membrane microdomains are involved in regulating the trafficking and amyloidegenic processing of amyloid precursor protein (25). Binding of β-amyloid to lipids may play an important role in maintaining the peptide in solution and thus be particularly relevant to β-amyloid's normal and pathologic biochemistry and physiology (26). Elevated dietary cholesterol has been shown to increase amyloid plaque formation in different in vivo models (27, 28), and cholesterol loading and cholesterol depletion have also been shown to affect β-amyloid generation, (29). Dietary cholesterol could induce Alzheimer-like β-amyloid immunoreactivity in rabbit brains (28), and disruption of cholesterol homeostasis in Alzheimer's disease has been linked to 13-amyloid pathology (30).

High density lipoprotein (HDL) cholesterol prevents aggregation and polymerization of β-amyloid (26). HDL cholesterol may also influence dementia risk through its anti inflammatory (31) and antioxidant (32) effects. In cross-sectional studies, lower HDL cholesterol levels have been associated with lower Mini-Mental State Examination scores (33) and with higher dementia (33, 34, and 35) and Alzheimer's disease (36) risks.

The associations between midlife lipid levels and late life dementia appear to be robust (37-40). However, the precise lipid that might be important remains unclear, with studies implicating high levels of LDL-C, (41, 42) or total cholesterol (TC) (37-39, 43) or low levels of high-density lipoprotein cholesterol (HDL-C) (44-50). HDL-C is critical for the maturation of synapses and the maintenance of synaptic plasticity (51). It can influence the formation of amyloid, the main constituent of amyloid plaques (52). Low HDL-C has also been shown to be associated with lower hippocampal volume (21).

A low level of HDL-C is a risk factor for cardiovascular disease. Recent studies suggest a robust association between low level of High Density Lipoprotein-Cholesterol (HDL-C)<40 mg/dL and poor memory. The Whitehall II study, (53) showed that association of low level of HDL-C with memory was independent of other lipids and identified HDL-C as being important for memory. There are different mechanisms connecting low levels of HDL-C and memory as HDL-C is a prominent lipoprotein in the human brain. It is involved in the regulation of amyloid beta protein metabolism and deposition in the brain. Deficit in HDL-C could affect memory through its influence on atherosclerotic disease and stroke. The linking of HDL-C to neurodegenerative diseases also involves its anti inflammatory or anti oxidant properties.

The supplementation of extract of fruits of Emblica officinalis has shown to increase the levels of HDL-C as well as decrease the levels of LDL-C and total cholesterol. The beneficial effect is documented in animal and human clinical studies (54-56). Since memory loss is linked with low levels of HDL-C, supplementation of extract of fruits of Emblica officinalis will have beneficial effect in increasing levels of HDL-C and improving memory. Memory deficit is critical to the diagnosis of cognitive impairment and Alzheimer's disease.

The present disclosure gives a composition of extracts of fruits of Emblica officinalis, a method of preparation of the said compositions of extract of fruits of Emblica officinalis and method of supplementing to patients with low HDL-C level, memory loss and dementia especially in patients with Alzheimer's disease giving therapeutically beneficial effect by increasing the level of HDL-C and improving the memory and cognition and for the treatment of Alzheimer's disease.

OBJECT OF THE INVENTION

The object of the invention is to provide a composition of the extracts of fruits of Emblica officinalis which has an application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

Another object of the present invention is to provide a method of preparing a composition of the extracts of fruits of Emblica officinalis which has an application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

Yet other object of the invention is to provide a method of supplementing the composition to the patients with low HDL-C level, memory loss and dementia especially in patients with Alzheimer's disease giving therapeutically beneficial effect by increasing the level of HDL-C and improving the memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

SUMMARY OF THE INVENTION

The present invention relates to a composition of the extract of fruits Emblica officinalis consisting of liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydro alcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis, a method of preparing such compositions of extract of fruits of Emblica officinalis, more particularly which has application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

DETAILED DESCRIPTION

Human studies show that low level of HDL-C is associated with poor memory and decline in HDL-C is associated with decline in memory over a 5 year period. Cognitive impairment is a key feature of neurodegenerative diseases like Alzheimer's disease. A method to increase the HDL-C can improve the cognitive functions and can offer a new approach to treat patients with neurodegenerative diseases with memory loss or dementia especially Alzheimer's disease. It may also offer a new method to prevent the impairment in cognitive functions especially memory.

The present disclosure provides a composition of the extract of fruits of Emblica officinalis, a method of preparing extract of fruits of Emblica officinalis more particularly which has application as a nutraceutical or pharmaceutical for increasing HDL-C levels in patients with memory loss and dementia especially in patients with neurodegenerative diseases like Alzheimer's disease and for the treatment of memory loss, dementia especially in Alzheimer's disease.

Some embodiments of the extract of fruits of Emblica officinalis include a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis, and combinations thereof.

The different extracts of fruits of Emblica officinalis are likely to differ in constituents. In some embodiments, a liquid juice of fruits of Emblica officinalis can include polyphenols, hydrolysable galloellagitannins, soluble and insoluble fiber, starch, sugar and carbohydrates. In some embodiments, a powder of an alcoholic extract of fruits of Emblica officinalis can include soluble fiber, soluble resin, fat and polyphenolic compounds present in the fruits of Emblica officinalis including hydrolysable galloellagitannins. In some embodiments, a powder of a hydroalcoholic extract of fruits of Emblica officinalis can include water soluble polyphenols, hydrolysable galloellagi tannins, soluble sugar and fiber. In some embodiments, a powder of a water extract of fruits of Emblica officinalis can include soluble polyphenols, hydrolysable galloellagi tannins, soluble fiber, carbohydrate and starch. In some embodiments, a powder of a juice of fruits of Emblica officinalis can include polyphenols, hydrolysable galloellagi tannins, soluble and insoluble fiber, starch, carbohydrate and sugar. In some embodiments, a powder of dried fruits of Emblica officinalis can include soluble and insoluble fiber, fat, sugar, organic acids like oxalic acids and polyphenolic compounds present in the fruits of Emblica officinalis including hydrolysable galloellagitannins. In some embodiments, a powder of a water extract of dried fruits of Emblica officinalis can include water soluble polyphenols, hydrolysable galloellagi tannins, soluble fiber, carbohydrate and starch. In some embodiments, a powder of a pectinase treated water extract of fruits of Emblica officinalis can include polyphenols, galloellagi tannins, simple sugars and soluble fibers.

In some embodiments, an extract of the fruits of Emblica officinalis can be provided in a dosage form selected from the group consisting of capsule, tablet, granule, sachet, powder, paste, ointment, infusion, injection, ampoule, solution, suspension, emulsion, pill, sustained release formulation and combinations thereof. An extract of the fruits of Emblica officinalis includes embodiments, such as, a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, a powder of a pectinase treated water extract of fruits of Emblica officinalis, and combinations thereof.

In some embodiments, the extract of fruits of Emblica officinalis includes about 12% to 70% polyphenols. In some embodiments, the extract of fruits of Emblica officinalis includes about 5% to about 35% hydrolysable gallo ellagic tannins.

In one embodiment of the method of preparing a powder of an alcoholic extract of fruits of Emblica officinalis, fresh fruits of Emblica officinalis having moisture 90% are pulverized and charged into an extractor. 95% methyl alcohol is pumped into the extractor and incubated. Then the solvent part is collected and fresh alcohol pumped again into the extractor. The extraction can be repeated thrice. All the extracts are pooled, filtered and dried in an Agitated thin film drier (ATFD) under a vacuum of about 700 mm Mercury. Dried product is discharged from the bottom of the vessel, pulverized and sieved through 30 meshes to obtain a powder of an alcoholic extract of fruits of Emblica officinalis. In some embodiments, the polyphenol content of the alcoholic extract can range from about 40% to about 70% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins can range from about 25% to about 35% by weight of the extract.

In one embodiment of the method of manufacture of a powder of a hydroalcoholic extract of fruits of Emblica officinalis, fresh fruits of Emblica officinalis are pulverized and charged into an extractor. Alcohol (methyl alcohol) water mixture (70:30) is pumped into the extractor and kept for a contact time of 3 hrs. Then the solvent part is collected and the fresh solvent pumped again into extractor and repeated thrice. All the extracts are pooled, filtered and concentrated in an Agitated thin film evaporator (ATFE). Then the concentrate is fed into vacuum stripper and dried under vacuum at above 500 mm of mercury. Dried product is discharged from the bottom of the vessel then pulverized and sieved through 30 mesh to obtain the dried hydro alcoholic powder of fruits of Emblica officinalis. In some embodiments, the polyphenol content of the extract ranges by weight from about 35% to about 65% by weight of the extract. In some embodiments, the hydrolysable galloellagic tannins range from about 25% to about 35% by weight of the extract.

In one embodiment of the method of manufacture of a powder of water extract of fruits of Emblica officinalis, fresh fruits of Emblica officinalis are pulverized and charged into an extractor. Water is pumped into the extractor and kept for a contact time of 3 hrs. Then the solvent part is collected and the fresh solvent pumped again into extractor and repeated thrice. All the extracts are pooled, filtered and concentrated in an evaporator. When the concentrate reaches the bottom of the vessel, the concentrate is fed into drier and dried under vacuum above 500 mm of mercury. Dried product is discharged from the bottom of the vessel, then pulverized and sieved through 30 meshes to obtain the powder of water extract of fruits of Emblica officinalis. In some embodiments, the polyphenol content of the extract ranges from about 35% to about 65% by weight of the extract. In some embodiments, the hydrolysable gallo ellagin tannins range from about 18% to about 35% by weight of the extract.

In one embodiment of the method of manufacture of a powder of juice of fruits of Emblica officinalis, fresh fruits of Emblica officinalis are collected and washed with water. The cleaned fruits are crushed in the screw expeller. The initial juice obtained on the tray of the screw expeller is collected in the feed tank under room temperature of 27° C. The initial juice is centrifuged to obtain filtrate which is collected and the residue which is removed. The collected filtrate is clarified in a rotating disc type clarifier (RPM-18000) to obtain final filtrate and some residue. After removing the residue, the final filtrate (clarified juice of Amla) is collected. This is dried in a spray drier which is set at inlet temperature 180° C. and outlet temperature 90° C., which is sieved through 30 meshes, to obtain a powder of juice of fruits of Emblica officinalis. In some embodiments, the polyphenol content ranges from about 35% to about 65% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins content ranges from about 20% to about 35% by weight of the extract.

In one embodiment of the method of manufacture of a powder of dried fruits of Emblica officinalis, fresh fruits of Emblica officinalis are collected and washed with water, chopped into flakes and dried in a hot air oven at around 110° C. for 10 hours. The dried material is powdered, sterilized under controlled temperature and passed through 30 mesh sieve to obtain powder of juice of fruits of Emblica officinals. In some embodiments, the polyphenol content ranges form about 12% to about 30% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins range from about 5-20% by weight of the extract.

In one embodiment of the method of manufacture of a powder of a water extract of dried fruits of Emblica officinalis, fresh fruits of Emblica officinalis are collected and washed with water, chopped into flakes and dried in a hot air oven at around 110° C. for 10 hours. Water is added into the dried flakes and kept for a contact time of 3 hrs. Then the solvent part is collected and the fresh solvent pumped again into dried flakes and repeated thrice. All the extracts are pooled, filtered and concentrated in an evaporator, when the concentrate reaches the bottom of the vessel; the concentrate is fed into drier and dried under vacuum above 500 mm of mercury. Dried product is discharged from the bottom of the vessel, then pulverized and sieved through 30 meshes to obtain a powder of a water extract of dried fruits of Emblica officinalis. In some embodiments, the polyphenol content ranges from about 30% to about 60% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins range from about 8% to about 25% by weight of the extract.

In one embodiment of method of manufacture of liquid juice of fruits of Emblica officinalis, fresh fruits of Emblica officinalis are collected, and washed with water. The cleaned fruits are crushed in the screw expeller. The initial juice obtained on the tray of the screw expeller is collected in the feed tank under room temperature of 27° C. The initial juice is centrifuged to obtain filtrate which is collected and the residue which is removed. The collected filtrate is clarified in a rotating disc type clarifier (RPM-18000) to obtain final filtrate and some residue. After removing the residue, the final filtrate (liquid juice of fruits of Emblica officinalis) is collected. In some embodiments, the polyphenol content ranges from about 12% to about 14% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins range from about 5% to about 7% by weight of the extract.

In one embodiment of the method of manufacture of a powder of a pectinase treated water extract of fruits of Emblica officinalis is by pulping fruits of Emblica officinalis with demineralized water to create slurry. The slurry is treated with pectinase and then filtered to obtain a solution. The solution is concentrated and dried under vacuum. Dried product is pulverized and sieved through 30 mesh to obtain a powder of the pectinase treated water extract of fruits of Emblica officinalis. In some embodiments the polyphenol content of the extract ranges from about 35% to about 65% by weight of the extract. In some embodiments, the hydrolysable gallo ellagic tannins range from about 16% to about 35% by weight of the extract.

In some embodiments, capsules having the extract of Emblica officinalis are prepared. A 500 mg capsule containing 500 mg of a powder of extract of fruits of Emblica officinalis is prepared by encapsulating the powder in hard gelatin capsules. The process is performed in an air-conditioned at 21° C. and de-humidified room. The extract powder is charged into the hopper of a semi-automatic capsule filling machine. ‘0’ size hard gelatin capsule shell is loaded to the tray and the extract powder is filled into the shell. The filled weight of capsules are checked simultaneously and these capsules are sorted by a sorting machine and polished with the help of a polishing machine to give capsules of 500 mg each.

A 250 mg capsule containing 250 mg powder of extract of fruits of Emblica officinalis can be prepared by encapsulating the powder in hard gelatin capsules. The process is performed in an air-conditioned at 21° C. and de-humidified room. The extract powder is charged into the hopper of a semi-automatic capsule filling machine. ‘2’ size hard gelatin capsule shell is loaded to the tray and the extract powder is filled into the shell. The filled weight of capsules are checked simultaneously and these capsules are sorted by a sorting machine and polished with the help of a polishing machine to give capsules of 250 mg each.

In some embodiments, an extract of fruits of Emblica officinalis can be administered at a dose of 500 mg capsules once daily for 4 months. Administration of 500 mg capsules of extract of fruits of Emblica officinalis including a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis once daily for 4 months to patients having low levels of HDL-C (below 40 mg/dL) resulted in an increase in the HDL-C level. Normal healthy subjects having HDL-C below 40 mg/dL given 500 mg capsules of each of the above mentioned extracts daily at night for 4 months showed an increase in HDL-C levels with the powder of juice of fruits of Emblica officinalis showing a maximum increase of 20% in HDL-C levels compared to placebo as seen in table:1.

Administration of the extract of fruits of Emblica officinalis include a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis resulted in increased HDL-C level and improved memory in patients with HDL-C below 40 mg/dL and having associated memory loss. As seen in Table 2, subjects having HDL-C levels below 40 mg/dL and short term memory loss given 250 mg capsules of the different extracts of fruits of Emblica officinalis twice daily for a period of 6 months showed an increase in HDL-C levels and an increase in memory as seen in Table 2. Among the different extracts, powder of water extract of fruits of Emblica officinalis is the most significant with a 25.7% increase in HDL-C levels and 30% increase in memory levels as seen in table: 2.

In some embodiments, administration of an extract of fruits of Emblica officinalis, including a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a water extract of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, or, a powder of a pectinase treated water extract of fruits of Emblica officinalis, 250 mg capsules twice daily for 6 months in patients with HDL-C is <40 mg/dl and MMSE score in the range 10 to 26 and 6CIT score of more than 8, resulted in an increased HDL-C level along with improvement in dementia as seen in table: 3. Of the different extracts of fruits of Emblica officinalis at a dose of 250 mg capsules twice daily for 6 months most significant improvement in the HDL-C level is seen in group of patients given powder of a water extract of Emblica officinalis. This increase also correlated with significant improvement in dementia assessed by MMSE and 6CIT scoring in the same group as seen in table: 3.

In some embodiments, administration of the extract of fruits of Emblica officinalis include a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis in patients with low levels of HDL-C (below 40 mg/dL) and probable Alzheimer's disease with the presence of mild to moderate dementia resulted in an increased HDL-C level along with improvement in cognition as seen in Table 4. Patients given alcoholic extracts of fruits of Emblica officinalis in a dose of 250 mg twice daily for 6 months showed maximum increase in HDL-C level which correlated with similar improvement in ADAS-cog scores compared to placebo as seen in table: 4. This signifies that the increase in HDL-C level is associated with improvement in the cognitive symptoms. It offers a new method of treating patients with Alzheimer's disease.

It will be readily understood by the skilled artisan that numerous alterations may be made to the examples and instructions given herein. These and other objects and features of present invention will be made apparent from the following examples. The following examples as described are not intended to be construed as limiting the scope of the present invention.

Example 1 Method of Manufacture of a Powder of an Alcoholic Extract of Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis (100 kilograms) having moisture 90% was pulverized and charged into an extractor. Around 200 liters of 95% methyl alcohol was pumped into the extractor and kept for a contact time of 3 hours. Then the solvent part was collected and fresh methyl alcohol pumped again into the extractor and extraction repeated thrice. All the extracts were pooled, filtered and dried in an Agitated thin film drier (ATM) which is working under vacuum 700 mm Mercury. Dried product (5 Kg) was discharged from the bottom of the vessel then pulverized and sieved through 30 mesh to obtain of powder of an alcoholic extract of fruits of Emblica officinalis.

The powder of the alcoholic extract of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 70% (Titration method) Hydrolysable gallo ellagictannins: 35% (HPTLC method)

Example 2 Method of Manufacture of a Powder of a Hydroalcoholic Extract of Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs was pulverized and charged into an extractor. Around 200 liters of methyl alcohol water mixture (70:30) was pumped into the extractor and kept for a contact time of 3 hrs. Then the solvent part collected and the fresh solvent pumped again into extractor and repeated thrice. All the extracts were pooled, filtered and concentrated in an Agitated thin film evaporator (ATFE) to TDS 30.0% (Total dissolved solids). Then the concentrate was fed into vacuum stripper and dried under vacuum at above 500 mm of mercury. Dried product (5 kg) is discharged from the bottom of the vessel, then pulverized and sieved through 30 meshes to obtain a powder of hydro alcoholic extract of fruits of Emblica officinalis.

The powder of the hydro alcoholic extract of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 65% (Titration method) Hydrolysable gallo ellagic tannins: 35% (HPTLC method)

Example 3 Method of Manufacture of a Powder of a Water Extract of Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs was pulverized and charged into an extractor. Around 200 Liters of water was pumped into the extractor and kept for a contact time of 3 hrs. Then the solvent part was collected and the fresh solvent pumped again into extractor and repeated thrice. All the extracts were pooled, filtered and concentrated in an evaporator, when the concentrate reaches the bottom of the vessel; the concentrate is fed into drier and dried under vacuum above 500 mm of mercury. Dried product (6 Kg) was discharged from the bottom of the vessel, then pulverized and sieved through 30 mesh to obtain a powder of a water extract of fruits of Emblica officinalis.

The powder of the water extract of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 60% (Titration method) Hydrolysable gallo ellagic tannins: 25% (HPTLC method)

Example 4 Method of Manufacture of Powder of Juice of Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs was collected, and washed with water. The cleaned fruits were crushed in the screw expeller. The initial juice obtained on the tray of the screw expeller was collected in the feed tank under room temperature of 27° C. The initial juice was centrifuged to obtain filtrate which was collected and the residue which was removed. The collected filtrate was clarified in a rotating disc type clarifier (RPM-18000) to obtain a final filtrate and some residue. After removing the residue, the final filtrate (clarified juice of Emblica officinalis) was collected with a yield 60-70% of fruits of Emblica officinalis with total dissolved solids (TDS) 4-7%. The final filtrate was dried in a spray drier set at inlet temperature 180° C. and outlet temperature 90° C. Around 3 kgs of product was obtained which was sieved through 30 mesh, to obtain the powder of a juice of fruits of Emblica officinalis.

The powder of the juice of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 62% (Titration method) Hydrolysable gallo ellagic tannins: 30% (HPTLC method)

Example 5 Method of Manufacture of Powder of Dried Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs were washed and chopped into flakes and dried in a hot air oven at around 110° C. for 10 hours. The dried material (9 kgs) was powdered, sterilized under controlled temperature and passed through a 30 mesh sieve to obtain a powder of dried fruits of Emblica officinalis.

The powder of dried fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 20% (Titration method) Hydrolysable gallo ellagic tannins: 12% (HPTLC method)

Example 6 Method of Manufacture of Powder of a Water Extract of Dried Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs was washed and chopped into flakes and dried in a hot air oven at around 110° C. for 10 hours. Around 200 Liters of water was added into the dried flakes and kept for a contact time of 3 hrs. Then the solvent part was collected and the fresh solvent was again added into flakes and repeated thrice. All the extracts were pooled, filtered and concentrated in an evaporator, when the concentrated water extract of dried fruit reached the bottom of the vessel, the concentrate was fed into drier and dried under vacuum above 500 mm of mercury. Dried product (6 kg) was discharged from the bottom of the vessel, then pulverized and sieved through 30 mesh to obtain a powder of the water extract of dried fruits of Emblica officinalis.

The powder of a water extract of dried fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 60% (Titration method) Hydrolysable gallo ellagic tannins: 20% (HPTLC method)

Example 7 Method of Manufacture of a Liquid Juice of Fruits of Emblica officinalis

Fresh fruits of Emblica officinalis 100 kgs was collected, and washed with water. The cleaned fruits were crushed in the screw expeller. The initial juice obtained on the tray of the screw expeller was collected in the feed tank under room temperature of 27° C. The initial juice was centrifuged to obtain filtrate which was collected and the residue which was removed. The collected filtrate was clarified in a rotating disc type clarifier (RPM-18000) to obtain final filtrate and some residue. After removing the residue, the final filtrate (clarified liquid juice of fruits of Emblica officinalis) was collected with a yield 60-70% of fruits of Emblica officinalis with total dissolved solids (TDS) 4-7%.

The liquid juice of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 12% (Titration method) Hydrolysable gallo ellagic tannins: 5% (HPTLC method)

Example 8 Method of Manufacture of Powder of a Pectinase Treated Water Extract of Fruits of Emblica officinalis

Pectinase treated water extract of fruits of Emblica officinalis was prepared by pulping fruits of Emblica officinalis 100 kg with demineralized water to create slurry. The slurry was treated with pectinase and then filtered to obtain a solution. The solution was concentrated and dried under vacuum. Dried product (5 kg) was pulverized and sieved through 30 mesh to obtain a powder of a pectinase treated water extract of fruits of Emblica officinalis.

The powder of pectinase treated water extract of fruits of Emblica officinalis was found to have the following composition. Polyphenol content: 64% (Titration method) Hydrolysable gallo ellagic tannins: 22% (HPTLC)

Example 9 Method of Manufacture of Placebo Capsules

10 kgs of raw rice was washed well and roasted in a rotatory paddle type roaster. The roasted rice (9.5 kg) was powdered and sterilized under controlled temperature which was passed through 30 mesh sieve to obtain fine powder of roasted rice.

A 500 mg placebo capsule containing 500 mg of a powder of roasted rice is prepared by encapsulating the powder in hard gelatin capsules. The process is performed in an air-conditioned at 21° C. and de-humidified room. 2 kg of powder is charged into the hopper of a semi-automatic capsule filling machine. ‘0’ size hard gelatin capsule shell is loaded to the tray and the extract powder is filled into the shell. The filled weight of capsules are checked simultaneously and these capsules are sorted by a sorting machine and polished with the help of a polishing machine to give 4000 placebo capsules of 500 mg each.

A 250 mg capsule containing 250 mg powder of roasted rice can be prepared by encapsulating the powder in hard gelatin capsules. The process is performed in an air-conditioned at 21° C. and de-humidified room. 2 kg of powder is charged into the hopper of a semi-automatic capsule filling machine. ‘2’ size hard gelatin capsule shell is loaded to the tray and the extract powder is filled into the shell. The filled weight of capsules are checked simultaneously and these capsules are sorted by a sorting machine and polished with the help of a polishing machine to give 8000 placebo capsules of 250 mg each.

Example 10 Method of Treating Patients with Low Levels of HDL-C

Different extracts of fruits of Emblica officinalis were studied on normal humans for a period of 4 months. A total of 27 subjects were divided into 9 groups of 3 subjects each. Both male and female patients of age between 35 and 65 years, having HDL-C below 40 mg/dL were selected for the study. Those subjects on cholesterol lowering drugs, diabetic subjects with history of cardiovascular, thyroid, hepatic and renal diseases were excluded from the study. The subjects were given one 500 mg capsule of extract of fruits of Emblica officinalis or placebo at night after food with water for 4 months. The results are given below in table: 1.

TABLE 1 HDL-C in HDL-C in mg/dL % change mg/dL (after from Type of extract Dose given (base line) treatment) baseline Powder of juice of 500 mg 35 42   +20% Emblica officinalis cap at night Group: A after food Powder of 500 mg 37 44 +18.9% Alcoholic extract of cap at night Emblica officinalis after food Group: B Powder of Hydro 500 mg 36 42 +16.67%  alcoholic cap at night Extract of Emblica after food officinalis Group: C Powder of Dried 500 mg 35 38 +8.57% fruit of Emblica cap at night officinalis after food Group: D Powder of Water 500 mg 38 44 +15.8% extract of Emblica cap at night officinalis Group: E after food Powder of Water 500 mg 37 43 +16.22%  extract of dried cap at night fruits of Emblica after food officinalis Group: F Powder of Water 500 mg 34 39 +14.71%  extract of Emblica cap at night officinalis treated after food with pectinase Group: G 10 ml Liquid juice 10 ml at night 34 37 +8.82% of fruits of Emblica after food officinalis Group: H Placebo 500 mg 36 35 −2.78% Group: I cap at night after food The study shows that supplementation of extract of fruits of Emblica officinalis significantly increases the levels of HDL-C in subjects compared to Placebo.

Example 11 Method of Treating Patients with Low Levels of HDL-C and Memory Loss

Subjects both male and female in the age group of 50-75 years having a HDL-C of <40 mg/dl were screened for the study. Short term verbal memory was assessed with a 20-word free recall test. Participants were presented a list of 20, 1- or 2-syllable words at 2-second intervals and were then asked to recall in writing as many of the words in any order and had 2 minutes to do so. Memory deficit corresponds to a recall of up to 4 words out of 20 words. Those subjects who could recall only 4 or less words were selected for the study. Twenty seven subjects thus selected were given 250 mg capsules of extract of Emblica officinalis twice daily.

Group A: Subjects were given 250 mg capsules twice daily. The capsules contained powder of an alcoholic extract of fruits of Emblica officinalis prepared as described in Example 1 Group B: Subjects were given 250 mg capsules twice daily. The capsules contained powder of a water extract of fruits of Emblica officinalis prepared as described in Example 3 Group C: Subjects were given 250 mg capsules twice daily. The capsules contained powder of a hydroalcoholic extract of fruits of Emblica officinalis prepared as described in Example 2 Group D: Subjects were given 250 mg capsules twice daily. The capsules contained powder of a juice of fruits of Emblica officinalis prepared as described in Example 4. Group E: Subjects were given 250 mg capsules twice daily. The capsules contained powder of dried fruits of Emblica officinalis prepared as described in Example 5. Group F: Subjects were given 250 mg capsules twice daily. The capsules contained powder of water extract of dried fruits of Emblica officinalis prepared as described in Example 6. Group G: Subjects were given 10 ml of liquid juice twice daily. The liquid juice of fruits of Emblica officinalis prepared as described in Example 7. Group H: Subjects were given 250 mg capsules twice daily. The capsules contained powder of a pectinase treated water extract of fruits of Emblica officinalis prepared as described in Example 8. Group I: Subjects were given 250 mg capsules twice daily. The capsules contained roasted rice powder prepared as described in Example 9. 250 mg capsules were given to the volunteers twice daily in the morning and night after food with water for 6 months.

Study assessments were made at baseline, 3 months and 6 months duration. The assessments include lipid profile and 20 word recall test. Table 2 gives the results of the study.

TABLE 2 % change from baseline Baseline 3 Study End to 6 Patient No: 0 month months 6 months months Powder of HDL 34 mg/dL 38 mg/dL 42 mg/dL +23.5% alcoholic 20 word 4/20 5/20 8/20   +20% extract of recall test Emblica score officinalis Group: A Powder of HDL 35 mg/dL 38 mg/dL 44 mg/dL +25.7% water extract 20 word 3/20 5/20 9/20   +30% of Emblica recall test officinalis score Group: B Powder of HDL 39 mg/dL 43 mg/dL 48 mg/dL   +23% hydroalcoholic 20 word 4/20 5/20 7/20   +15% extract of recall test Emblica score officinalis Group: C Powder of HDL 33 mg/dL 36 mg/dL 41 mg/dL +24.2% juice of 20 word 3/20 4/20 7/20   +20% Emblica recall test officinalis score Group: D Powder of HDL 40 mg/dL 41 mg/dL 44 mg/dL   +10% dried fruit of 20 word 4/20 5/20 8/20   +20% Emblica recall test officinalis score Group: E Powder of HDL 35 mg/dL 39 mg/dL 41 mg/dL +17.1% water extract of 20 word 4/20 4/20 6/20   +10% dried fruits of recall test Emblica score officinalis Group: F 10 ml Liquid HDL 37 mg/dL 39 mg/dL 41 mg/dL +10.8% juice of fruits 20 word 4/20 5/20 7/20   +15% of Emblica recall test officinalis score Group: G Powder of HDL 36 mg/dL 40 mg/dL 43 mg/dL +19.4% water extract 20 word 3/20 5/20 8/20   +25% of dried fruits recall test of Emblica score officinalis treated with pectinase Group: H Placebo HDL 37 37 36 −2.7% Group: I 20 word 4/20 4/20 3/20   −5% recall test score

All the subjects at the end of 6 months benefited from the supplementation of extracts of Emblica officinalis twice daily. The HDL-C value of all the subjects increased and there was also improvement in the word recall test score indicating a beneficial effect on memory enhancement. The changes were appreciable even at 3 months. All patients treated with extract of Emblica officinalis and the care givers approved of the general well being and rejuvenation experienced by the patients.

Example 12 Method of Treatment of Patients with Low Levels of HDL-C, Memory Loss and Cognitive Impairment with Extracts of Fresh Fruits of Emblica officinalis

Both male and female patients, aged 45 years or older, were eligible for the study if their HDL-C is <40 mg/dl and have memory loss documented by a Mini-Mental State Examination (MMSE) score (57), in the range 10 to 26 and 6 item Cognitive Impairment Test (6CIT) score (58), of more than 8. Patients also weighed between 50 and 80 kg and had a stable medical condition for 3 months prior to screening, and an absence of clinically significant focal lesion on CT scan.

Patients were ineligible if they were on treatment with antidepressants, tranquilizers, mood stabilizers etc which would interfere with the study assessments. The objectives and implications of the study were explained to the patients and their care givers. The eligible patients were screened for the lipid profile and assessed with MMSE and 6 CIT for memory loss.

MMSE is one of the most commonly used tools to assess memory, concentration, and other cognitive skills. It is a research-based set of questions that provides a score about a person's general level of impairment. The MMSE has questions that assess five areas: orientation, short term memory (retention), attention, short term memory (recall) and language. The maximum score on MMSE is 30. A score of 24-30 is considered a normal range and a score below it is indicative of dementia. The 6CIT is a useful dementia screening tool in Primary Care. The 6CIT uses an inverse score and questions are weighted to produce a total score out of 28. Scores of 0-7 are considered normal and 8 or more are considered significant. The test has high sensitivity without compromising specificity even in mild dementia.

The 15 subjects who fulfilled the study criteria were enrolled into 5 groups of 3 each in the study. 250 mg capsules were given twice daily: once in the morning and once at night after food with water for 6 months.

Group A: Subjects were given 250 mg capsules of a powder of an alcoholic extract of fruits of Emblica officinalis twice daily for 6 months. The extract was prepared as described in Example 1

Group B: Subjects were given 250 mg capsules of powder of a water extract of fruits of Emblica officinalis twice daily for 6 months. The extract was prepared as described in Example 3

Group C: Subjects were given 250 mg capsules of a powder of a hydroalcoholic extract of fruits of Emblica officinalis twice daily for 6 months. The extract was prepared as described in Example 2

Group D: Subjects were given 250 mg capsules of a powder of a pectinase treated water extract of fruits of Emblica officinalis twice daily for 6 months. The extract was prepared as described in Example 8

Group E: Subjects were given 250 mg capsules of a powder of water extract of dried fruits of Emblica officinalis twice daily for 6 months. The extract was prepared as described in Example 6

The study assessments were made at baseline, 3 months and 6 months duration. The assessments included lipid profile, MMSE and 6 CIT scoring. Results of the study are provided in Table 3 below.

TABLE 3 % change from baseline Baseline Study End to 6 Patient No: 0 month 3 months 6 months months Powder of HDL 35 mg/dL 40 mg/dL 43 mg/dL +22.8% alcoholic MMSE 20/30 21/30 23/30   +10% extract of 6CIT 14/28 12/28 10/28   +14% Emblica officinalis Group: A Powder of HDL 33 mg/dL 38 mg/dL 41 mg/dL +24.2% water extract MMSE 16/30 19/30 22/30   +20% of Emblica 6CIT 14/28 12/28 8/28 +21.4% officinalis Group: B Powder of HDL 36 mg/dL 41 mg/dL 44 mg/dL +22.2% hydroalcoholic MMSE 22/30 23/30 26/30   +13% extract of 6CIT 12/28 12/28 10/28   +7% Emblica officinalis Group: C Powder of HDL 35 mg/dL 39 mg/dL 42 mg/dL   +20% water extract of MMSE 18/30 20/30 21/30   +10% Emblica 6CIT 10/28 8/28 6/28   +14% officinalis treated with pectinase Group: D Powder of a HDL 35 38 41 +17.1% water extract MMSE 20/30 22/30 23/30   +10% of dried fruits 6CIT 11/28 10/28 8/28 +10.7% of Emblica officinalis, Group: E

As seen in Table 3, at the end of study all subjects performed better with MMSE and 6CIT, showing that administration of extract of Emblica officinalis as 250 mg capsules twice daily significantly improved dementia by enhancing the memory and cognitive ability along with the elevation of HDL-C.

Example 13 Method of Treatment of Patients with Alzheimer's Disease with Extracts of Fresh Fruits of Emblica officinalis

Patients aged between 60 and 80 years of either sex with HDL-C less than 40 mg/dL with a history of gradual and progressive cognitive decline for at least six months, diagnosis of probable Alzheimer's disease according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) and presence of mild to moderate dementia (score of >12 on the cognitive subscale of Alzheimer's disease assessment scale (ADAS-cog) (59) were selected for the study. Patients were excluded if they are having any significant systemic diseases, psychiatric illness or any drugs affecting the cognitive functions.

ADAS-cog is a subscale of 11 items that evaluates selected aspects of attention, language, memory, orientation, praxis, and reasoning. Scores for ADAS-cog range from 0 to 70 (very severe).

The study subjects were given 250 mg capsules of extract of Emblica officinalis twice daily for 6 months. A total of 27 subjects were selected for the study. They were divided into 9 groups of 3 subjects each.

-   Group I: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of an alcoholic extract of fruits of     Emblica officinalis prepared as described in Example 1 -   Group II: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of a water extract of fruits of Emblica     officinalis prepared as described in Example 3 -   Group III: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of a hydroalcoholic extract of fruits of     Emblica officinalis prepared as described in Example 2 -   Group IV: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of water extract of dried fruits of     Emblica officinalis prepared as described in Example 6. -   Group V: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of a pectinase treated water extract of     fruits of Emblica officinalis prepared as described in Example 8. -   Group VI: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of dried fruits of Emblica officinalis     prepared as described in Example 5. -   Group VII: Subjects were given 10 ml of liquid juice twice daily.     The liquid juice of fruits of Emblica officinalis prepared as     described in Example 7. -   Group VIII: Subjects were given 250 mg capsules twice daily. The     capsules contained powder of a juice of fruits of Emblica     officinalis prepared as described in Example 4. -   Group IX: Subjects were given 250 mg capsules twice daily. The     capsules contained roasted rice powder prepared as described in     Example 9.     The study visits were done at baseline, 3 months and 6 months. The     results are provided in Table 4.

TABLE 4 % change from Baseline Study baseline (0 End to 6 Groups month) 3 months 6 months months Group I Powder of ADAS- 26 24 18 +30.7%   alcoholic cog score extract HDL-C 38 42 46 +21% Emblica officinalis 250 mg Group II Powder of ADAS- 27 24 19 +29.6%   water extract cog score of Emblica HDL-C 33 37 39 +18% officinalis 250 mg Group Powder of ADAS- 26 24 20 +23% III hydroalcoholic cog score extract of HDL-C 35 38 41 +17% Emblica officinalis 250 mg Group Powder of ADAS- 28 25 21 +25% IV water extract cog score of dried fruits HDL-C 34 37 40 +17.6%   of Emblica officinalis 250 mg Group V Powder of a ADAS- 26 23 19 +26.9%   pectinase cog score treated water HDL-C 38 41 45 +18% extract of Emblica officinalis 250 mg Group Powder of ADAS- 27 26 23 +14.8%   VI dried fruits of cog score Emblica HDL-C 35 38 42 +20% officinalis 250 mg Group Liquid juice ADAS- 26 24 22 +15% VII of fruits of cog score Emblica HDL-C 38 41 45 +18% officinalis 10 ml Group Powder of a ADAS- 25 22 20 +20% VIII juice of fruits cog score of Emblica HDL-C 36 40 42 +16.6%   officinalis 250 mg Group Placebo ADAS- 26 28 32 +23% IX capsule cog score 250 mg HDL-C 38 36 35 +7.8% 

As seen in Table 4, there were no significant differences between the groups at baseline (week 0) on the ADAS-cog rating scale. In groups given different extracts of Emblica officinalis there were significant change on the ADAS-cog rating scale scores compared to placebo. The improvement in the ADAS-cog score was significant over a period of 6 months, which was seen even at 3 months of treatment. This study showed that patients with mild to moderate Alzheimer's disease receiving an extract Emblica officinalis experienced significant benefits in cognition with 6 months of treatment. The extract of fruits of Emblica officinalis may offer an effective method of treating patients with dementia and Alzheimer's disease and for slowing the progress of Alzheimer's disease.

Other modifications and variations to the invention will be apparent to those skilled in the art from the foregoing disclosure and teachings. Thus, while only certain embodiments of the invention have been specifically described herein, it will be apparent that numerous modifications may be made thereto without departing from the spirit and scope of the invention.

REFERENCES

-   1. Kral V A, Neuro-psychiatric observations in an old peoples home:     studies of memory dysfunction in senescence, J Gerontol, 13:169-176     (1958) -   2. Petersen R C, Smith G, Kokmen E, Ivnik R J, Tangalos E G, Memory     function in normal aging. Neurology, 42:396-401 (1992) -   3. Youngjohn J R, Crook T H III, Learning, forgetting, and retrieval     of everyday material across the adult life span, J Clin Exp     Neuropsychol, 15:447-460 (1993) -   4. Mitrushina M, Satz P, Changes in cognitive functioning associated     with normal Aging, Arch Clin Neuropsychol, 6:49-60 (1991) -   5. Small S A, Stern Y, Tang M, Mayeux R, Selective decline in memory     function among healthy elderly, Neurology, 52:1392-1396 (1999). -   6. Craik F I M, McDowd J M, Age differences in recall and     recognition, J Exp Psychol Learn Mem Cogn, 13:474-479 (1987). -   7. Zelinski E M, Gilewski M J, Schaie K W, Individual differences in     cross-sectional and 3-year longitudinal memory performance across     the adult life span, Psychol Aging, 8:176-186 (1993). -   8. Rubin E H, Storandt M, Miller J P, et al. A prospective study of     cognitive function and onset of dementia in cognitively healthy     elders, Arch Neurol, 55:395-401 (1998). -   9. Hanninen T, Koivisto K, Reinikainen K J, et al. Prevalence of     ageing-associated cognitive decline in an elderly population, Age     Ageing, 25:201-205. (1996). -   10. Rapp P R, Amaral D G, Individual differences in the cognitive     and neurobiological consequences of normal aging, Trends Neurosci,     15:340-345 (1992). -   11. Diehl M, Willis S L, Schaie K W, et al. Everyday problem solving     in older adults: observational assessment and cognitive correlates,     Psychol Aging, 10: 478-491 (1995). -   12. Hultsch D F, Hammer M, Small B J, Age differences in cognitive     performance in later life: relationships to self-reported health and     activity life style, J Gerontol, 48:1-11 (1993). -   13. Albert S A, Michaels K, Padilla M, et al. Functional     significance of mild cognitive impairment in elderly patients     without a dementia diagnosis, Am J Geriatr Psychiatry, 7:213-220     (1999). -   14. Braak H, Braak E, Evolution of the neuropathology of Alzheimer's     disease, Acta Neurol Scand Suppl, 165:3-12 (1996). -   15. Masur D M, Sliwinski M, Lipton R B, Blau A D, Crystal H A,     Neuropsychological prediction of dementia and the absence of     dementia in healthy elderly persons, Neurology, 44:1427-1432 (1994) -   16. Jacobs D M, Sano M, Dooneief G, Marder K, Bell K L, Stern Y,     Neuropsychological detection and characterization of preclinical     Alzheimer's disease, Neurology, 45:957-962 (1995). -   17. Small G W, Rabins P V, Barry P P, et al. Diagnosis and treatment     of Alzheimer disease and related disorders, Consensus statement of     the American Association for Geriatric Psychiatry, the Alzheimer's     Association, and the American Geriatrics Society, JAMA 278:1363-71     (1997). -   18. Morris J C, Dementia update 2005, Alzheimer Dis Assoc Disord,     19:100-17 (2005). -   19. Tschanz J T, Corcoran C, Skoog I, et al. Dementia: the leading     predictor of death in a defined elderly population: the Cache County     Study, Neurology, 62:1156-62 (2004). -   20. Jurevics H, Morell P, Cholesterol for synthesis of myelin is     made locally, not imported into brain, J Neurochem, 64: 895-901     (1995). -   21. Michikawa M, Cholesterol paradox: is high total or low HDL     cholesterol level a risk for Alzheimer's disease? J Neurosci Res,     72:141-6 (2003). -   22. Koudinov A R, Koudinova N V, Essential role for cholesterol in     synaptic plasticity and neuronal degeneration, FASEB J, 15:1858-60     (2001). -   23. Mauch D H, Nagler K, Schumacher S, et al. CNS synaptogenesis     promoted by glia-derived cholesterol, Science, 294:1354-7 (2001). -   24. Fan Q W, Yu W, Senda T, et al. Cholesterol-dependent modulation     of tau phosphorylation in cultured neurons, J Neurochem, 76:391-400     (2001). -   25. Vetrivel K S, Cheng H, Lin W, et al. Association of     gammasecretase with lipid rafts in post-Golgi and endosome     membranes. J Biol Chem, 279:44945-54 (2004). -   26 Koudinov A R, Berezov T T, Kumar A, et al. Alzheimer's amyloid     beta interaction with normal human plasma high density lipoprotein:     association with apolipoprotein and lipids, Clin Chim Acta,     270:75-84 (1998). -   27. Refolo L M, Malester B, LaFrancois J, et al.     Hypercholesterolemia accelerates the Alzheimer's amyloid pathology     in a transgenic mouse model, Neurobiol Dis, 7:321-31 (2000). -   28. Sparks D L, Scheff S W, Hunsaker J C 3rd, et al. Induction of     Alzheimer-like beta-amyloid immunoreactivity in the brains of     rabbits with dietary cholesterol, Exp Neurol, 126: 88-94 (1994). -   29. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion     inhibits the generation of beta-amyloid in hippocampal neurons, Proc     Natl Acad Sci USA, 95:6460-4 (1998). -   30. Eckert G P, Kirsch C, Leutz S, et al. Cholesterol modulates     amyloid beta-peptide's membrane interactions, Pharmacopsychiatry,     36(suppl 2):S136-43 (2003). -   31. Cockerill G W, Huehns T Y, Weerasinghe A, et al. Elevation of     plasma high-density lipoprotein concentration reduces     interleukin-1-induced expression of E-selectin in an in vivo model     of acute inflammation, Circulation, 103:108-12 (2001). -   32. Paterno R, Ruocco A, Postiglione A, et al. Reconstituted high     density lipoprotein exhibits neuroprotection in two rat models of     stroke, Cerebrovasc Dis, 17:204-11 (2004). -   33. van Exel E, de Craen A J, Gussekloo J, et al. Association     between high-density lipoprotein and cognitive impairment in the     oldest old. Ann Neurol, 51:716-21 (2002) -   34. Wolf H, Hensel A, Arendt T, et al. Serum lipids and hippocampal     volume: the link to Alzheimer's disease? Ann Neurol, 56:745-8     (2004). -   35. Bonarek M, Barberger-Gateau P, Letenneur L, et al. Relationships     between cholesterol, apolipoprotein E polymorphism and dementia: a     cross-sectional analysis from the PAQUID study, Neuroepidemiology,     19:141-8 (2000) -   36. Merched A, Xia Y, Visvikis S, et al. Decreased high-density     lipoprotein cholesterol and serum apolipoprotein AI concentrations     are highly correlated with the severity of Alzheimer's disease,     Neurobiol Aging, 21:27-30, (2000) -   37. Notkola interleukin (IL), Sulkava R, Pekkanen J, Erkinjuntti T,     Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A. Serum total     cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's     disease. Neuroepidemiology. 17:14-20 (1998). -   38. Stewart R, White L R, Xue Q L, Launer L J, Twenty-six-year     change in total cholesterol levels and incident dementia: the     Honolulu-Asia Aging Study, Arch Neurol, 64:103-107 (2007). -   39. Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A,     Tuomilehto J, Soininen H, Kivipelto M, Serum cholesterol changes     after midlife and late-life cognition: twenty-one-year follow-up     study, Neurology, 68:751-756 (2007). -   40. Saczynski J S, White L, Peila R L, Rodriguez B L, Launer L J,     The relation between apolipoprotein A-I and dementia: the     Honolulu-Asia aging study, Am J Epidemiol, 165:985-992 (2007). -   41. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein     levels, statin use, and cognitive function in older women, Arch     Neurol, 59:378-384 (2002). -   42. Moroney J T, Tang M X, Berglund L, Small S, Merchant C, Bell K,     Stern Y, Mayeux R, Low-density lipoprotein cholesterol and the risk     of dementia with stroke, JAMA, 282:254-260 (1999) -   43. Evans R M, Hui S, Perkins A, Lahiri D K, Poirier J, Farlow M R,     Cholesterol and APOE genotype interact to influence Alzheimer     disease progression, Neurology, 62:1869-1871 (2004). -   44. Reitz C, Tang M X, Luchsinger J, Mayeux R, Relation of plasma     lipids to Alzheimer disease and vascular dementia, Arch Neurol, 61:     705-714 (2004). -   45. Razay G, Vreugdenhil A, Wilcock G, The metabolic syndrome and     Alzheimer disease, Arch Neurol, 64:93-96 (2007) -   46. Komulainen P, Lakka T A, Kivipelto M, Hassinen M, Helkala E L,     Haapala I, Nissinen A, Rauramaa R, Metabolic syndrome and cognitive     function: a population-based follow-up study in elderly women,     Dement Geriatr Cogn Disord, 23:29-34 (2007). -   47. Wolf H, Hensel A, Arendt T, Kivipelto M, Winblad B, Gertz H J,     Serum lipids and hippocampal volume: the link to Alzheimer's     disease? Ann Neurol, 56:745-748 (2004). -   48. van E E, de Craen A J, Gussekloo J, Floux P, Bootsma-van der WA,     Macfarlane P W, Blauw G J, Westendorp R G, Association between high     density lipoprotein and cognitive impairment in the oldest old, Ann     Neurol, 51:716-721 (2002). -   49. Katzman R, Aronson M, Fuld P, Kawas C, Brown T, Morgenstern H,     Frishman W, Gidez L, Eder H, Ooi W L, Development of dementing     illnesses in an 80-year-old volunteer cohort, Ann Neurol, 25:     317-324 (1989). -   50. Muckle T J, Roy J R, High-density lipoprotein cholesterol in     differential diagnosis of senile dementia, Lancet, 1:1191-1193     (1985). -   51. Michikawa M, Cholesterol paradox: is high total or low HDL     cholesterol level a risk for Alzheimer's disease? J Neurosci Res,     72: 141-146 (2003). -   52. Olesen O F, Dago L, High density lipoprotein inhibits assembly     of amyloid beta-peptides into fibrils, Biochem Biophys Res Commun,     270:62-66 (2000). -   53. Archana Singh-Manoux, David Gimeno, Mika Kivimaki, Eric Brunner     and Michael G, Marmot, Low HDL Cholesterol Is a Risk Factor for     Deficit and Decline in Memory in Midlife, The Whitehall H Study     Arterioscler Thromb Vasc Biol, p 1557-1563 (August 2008) -   54. Effect standardized of amla extract on atherosclerosis and     dyslipidemia., Ind. J. Pharm. Sci, 68 (4), 437-441, (2006) -   55. Amlamax™ in the Management of Dyslipidemia in Humans Ind. J.     Pharm. Sci, 70(4): 504-507, (2008) -   56. A pilot clinical study to evaluate the effect of emblica     officinalis extract (Amlamax™) on markers of systemic inflammation     and dyslipidemia Ind. J. Clin. Biochem, 23(4): 378-381 (2008) -   57. Folstein M F, Folstein S E, McHugh PR, “Mini-mental state.” A     practical method for grading the cognitive state of patients for the     clinician, J Psychiatr Res, 12:189-198 (1975) -   58. Brooke P and Bullock R, Validation of a 6-item cognitive     impairment test with a view to primary care usage, International J.     Geriatric Psychiatry, 14 (11): 936-40 (1999). -   59. Rosen W G, et al. Am J Psychiatry. 141:1356-1364 (1984). 

1. An extract of fruits of Emblica officinalis selected from the group consisting of a liquid juice of fruits of Emblica officinalis, a powder of an alcoholic extract of fruits of Emblica officinalis, a powder of a hydroalcoholic extract of fruits of Emblica officinalis, a powder of a water extract of fruits of Emblica officinalis, a powder of a juice of fruits of Emblica officinalis, a powder of dried fruits of Emblica officinalis, a powder of a water extract of dried fruits of Emblica officinalis, and, a powder of a pectinase treated water extract of fruits of Emblica officinalis.
 2. The extract of fruits of Emblica officinalis of claim 1, comprising about 12% to 70% polyphenols.
 3. The extract of fruits of Emblica officinalis of claim 1, comprising about 5% to about 35% hydrolysable gallo ellagic tannins.
 4. A dosage form comprising the extract of fruits of Emblica officinalis as claimed in claim 1, wherein the dosage form selected from the group consisting of a capsule, tablet, granule, sachet, powder, paste, ointment, infusion, injection, ampoule, solution, suspension, emulsion, pill, sustained release formulation and combinations thereof.
 5. A method of preparing a liquid juice of Emblica officinalis comprising: crushing fresh fruits of Emblica officinalis to obtain an initial juice; separating an initial filtrate and a residue from the initial juice; rotating the initial filtrate in a rotating disc type clarifier to obtain a final filtrate and a final residue; removing the final residue from the final filtrate to generate the liquid juice of Emblica officinalis.
 6. A method of preparing a powder of an alcoholic extract of fruits of Emblica officinalis comprising: pulverizing raw fruits of Emblica officinalis to obtain a pulp; charging the pulp into an extractor, adding 95% alcohol into the extractor and incubating with the pulp for 3 hours to obtain an alcohol supernatant and a residue; removing the alcohol supernatant from the extractor; filtering the alcohol supernatant to obtain a filtered alcohol supernatant; drying the filtered alcohol supernatant in an agitated thin film drier under a vacuum of about 600 to about 700 mm mercury to obtain a dried alcohol supernatant; pulverizing the dried alcohol supernatant to obtain a pulverized alcohol supernatant; sieving the pulverized alcohol supernatant to obtain the powder of the alcoholic extract of the fruits of Emblica officinalis.
 7. A method of preparing a powder of a hydroalcoholic extract of fruits of Emblica officinalis by a process comprising: pulverizing raw fruits of Emblica officinalis to obtain a pulp; charging the pulp into an extractor, adding an alcohol: water mixture to the extractor, incubating for 3 hours to form a hydroalcoholic supernatant and a residue; collecting the hydroalcoholic supernatant; filtering the supernatant to obtain a filtered hydroalcoholic supernatant; concentrating the filtered hydroalcoholic supernatant to obtain a concentrated hydroalcoholic supernatant; and, drying the concentrated hydroalcoholic supernatant to obtain the powder of the hydroalcoholic extract of fruits of Emblica officinalis.
 8. A method of preparing a powder of a water extract of fruits of Emblica officinalis by a process comprising: pulverizing raw fruits of Emblica officinalis to obtain a pulp; charging the pulp into an extractor, adding water to the pulp in the extractor, incubating the water and the pulp for 3 hours to obtain a water supernatant and a residue; removing the water supernatant from the extractor; filtering the water extract to obtain a filtered water extract; concentrating the filtered water extract to obtain a concentrated water extract; and, drying the concentrated water extract to obtain the powder of the water extract of fruits of Emblica officinalis
 9. A method of preparing a powder of a juice extract of fruits of Emblica officinalis by a process comprising: crushing fresh fruits of Emblica officinalis to obtain an initial juice; centrifuging the initial juice to obtain an initial filtrate and an initial residue; separating the initial filtrate from the initial residue to obtain a separated initial filtrate; clarifying the separated initial filtrate to obtain a final filtrate and a final residue; separating the final filtrate from the final residue to obtain a separated final filtrate; drying the final filtrate to obtain a dried powder; and, sieving the dried powder to obtain the powder of the juice of fruits of Emblica officinalis.
 10. A method of preparing a powder of dried fruits of Emblica officinalis by a process comprising: chopping fresh fruits of Emblica officinalis to obtain flakes of fruits of Emblica officinalis; drying the flakes of fruits of Emblica officinalis at 110° C. for about 10 hours to obtain dried flakes of fruits of Emblica officinalis; powdering the dried flakes to obtain a powder; sterilizing the powder to obtain a sterilized powder; sieving the sterilized powder through a 30 mesh sieve to obtain the powder of dried fruits of Emblica officinalis.
 11. A method of preparing a powder of a water extract of dried fruits of Emblica officinalis by a process comprising: chopping fresh fruits of Emblica officinalis to obtain flakes of fruits of Emblica officinalis; drying the flakes of fruits of Emblica officinalis at 110° C. for about 10 hours to obtain dried flakes of fruits of Emblica officinalis; adding water to the dried flakes of fruits of Emblica officinalis, incubating for 3 hours to obtain a water supernatant and a residue; separating the water supernatant from the residue to obtain a separated water supernatant; filtering the separated water supernatant to obtain a filtered water supernatant; concentrating the filtered water supernatant to obtain a concentrated water supernatant; drying the concentrated water supernatant in a vacuum stripper under vacuum at about 500 mm mercury to obtain a dried water supernatant; pulverizing the dried water supernatant to obtain a pulverized dried water supernatant; and, sieving the pulverized dried water supernatant to obtain the powder of the water extract of the dried fruits of Emblica officinalis.
 12. A method of preparing a powder of a pectinase treated water extract fruits of Emblica officinalis by a process comprising: pulping fruits of Emblica officinalis with demineralized water to create a slurry; treating the slurry with pectinase; filtering the slurry to obtain a solution; concentrating the solution to obtain a concentrate; and, drying the concentrate under vacuum to generate the powder of the pectinase treated water extract fruits of Emblica officinalis.
 13. A method of increasing HDL cholesterol levels in a patient in need thereof, comprising administering an extract of fruits of Emblica officinalis as claimed in claim
 1. 14. The method as claimed in claim 13, wherein the patient is selected from the group consisting of a patient having memory loss, a patient having Alzheimer's, and combinations thereof. 